Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Colorcon
US Army
Express Scripts
Chinese Patent Office
Covington
Citi
QuintilesIMS
Fuji
Federal Trade Commission

Generated: February 17, 2018

DrugPatentWatch Database Preview

ALTOPREV Drug Profile

« Back to Dashboard

Which patents cover Altoprev, and when can generic versions of Altoprev launch?

Altoprev is a drug marketed by Covis Pharma Bv and is included in one NDA. There is one patent protecting this drug.

This drug has seven patent family members in five countries.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the lovastatin profile page.
Summary for ALTOPREV
Drug patent expirations by year for ALTOPREV
Pharmacology for ALTOPREV
Medical Subject Heading (MeSH) Categories for ALTOPREV

US Patents and Regulatory Information for ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Covis Pharma Bv ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ALTOPREV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,440,387 Methods for determining risk of Alzheimer's disease ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Moodys
Merck
Boehringer Ingelheim
US Army
Queensland Health
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot